ArticleAnnals of hematology2026
A Multi-Omics and machine learning platelet-related prognostic signature in multiple myeloma.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
While platelets are well-documented contributors to tumorigenesis, their role in multiple myeloma (MM) progression and risk stratification remains underexplored. To assess platelet function in MM and verify the prognostic value of platelet-related genes(PRGs) in patients with multiple myeloma, further providing new ideas for the development of MM. We combined the clinical assessment of platelet activation in MM patients with functional co-culture experiments using MM cell lines (RPMI8226, MM.1 S) to investigate platelet-driven tumor progression. Additionally, an integrated analysis of bulk (GSE124310) and single-cell transcriptomic datasets (GSE6477, TCGA-MM data, GSE4581, GSE24080,and GSE136337) was performed to identify platelet-related prognostic genes (PRGs). Through single-cell RNA sequencing, we identified aberrant erythroid-megakaryocyte components in multiple myeloma and further demonstrated dysfunctional platelet activity that promotes tumor cell proliferation and suppresses apoptosis. Using comprehensive bioinformatic screening across 116 algorithms, we identified a combined forward stepwise Cox and Ridge regression model as optimal and established a 13-gene platelet-related prognostic signature. The genetic risk model effectively stratified MM patients into distinct prognostic groups, with high-risk patients exhibiting poorer outcomes in both training and validation cohorts. Finally, we integrated the genetic risk model and clinically relevant information and visualized it with dynamic Nomogram plots, and the ROC and DCA curves demonstrated that the integrated model had better predictive ability. Our study establishes a significant association between platelet activity and disease progression in MM. The platelet-related prognostic signature we developed is correlated with patient outcomes and may have utility in risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.